These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 8087864)

  • 1. Induction of cAMP-dependent protein kinase (PKA) activity in T cells after stimulation of the prostaglandin E2 or the beta-adrenergic receptors: relationship between PKA activity and inhibition of anti-CD3 monoclonal antibody-induced T cell proliferation.
    Bauman GP; Bartik MM; Brooks WH; Roszman TL
    Cell Immunol; 1994 Oct; 158(1):182-94. PubMed ID: 8087864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modulation of T cell proliferation by stimulation of the beta-adrenergic receptor: lack of correlation between inhibition of T cell proliferation and cAMP accumulation.
    Bartik MM; Brooks WH; Roszman TL
    Cell Immunol; 1993 May; 148(2):408-21. PubMed ID: 8388322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Costimulatory signals modulate the antiproliferative effects of agents that elevate cAMP in T cells.
    Bartik MM; Bauman GP; Brooks WH; Roszman TL
    Cell Immunol; 1994 Oct; 158(1):116-30. PubMed ID: 8087859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. beta-Agonist enhances type 2 T-cell survival and accumulation.
    Loza MJ; Peters SP; Foster S; Khan IU; Penn RB
    J Allergy Clin Immunol; 2007 Jan; 119(1):235-44. PubMed ID: 17208607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EP4/EP2 receptor-specific prostaglandin E2 regulation of interleukin-6 generation by human HSB.2 early T cells.
    Zeng L; An S; Goetzl EJ
    J Pharmacol Exp Ther; 1998 Sep; 286(3):1420-6. PubMed ID: 9732406
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandin E2 acts at two distinct pathways of T lymphocyte activation: inhibition of interleukin 2 production and down-regulation of transferrin receptor expression.
    Chouaib S; Welte K; Mertelsmann R; Dupont B
    J Immunol; 1985 Aug; 135(2):1172-9. PubMed ID: 2989362
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dexamethasone and prostaglandin E2 modulate T-cell receptor signaling through a cAMP-independent mechanism.
    Elliott LH; Levay AK; Sparks B; Miller M; Roszman TL
    Cell Immunol; 1996 Apr; 169(1):117-24. PubMed ID: 8612284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of agonist stimulation of cAMP-dependent protein kinase and G protein-coupled receptor kinase phosphorylation of the beta2-adrenergic receptor using phosphoserine-specific antibodies.
    Tran TM; Friedman J; Qunaibi E; Baameur F; Moore RH; Clark RB
    Mol Pharmacol; 2004 Jan; 65(1):196-206. PubMed ID: 14722251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of anti-CD3 monoclonal antibody-induced T-cell proliferation by dexamethasone, isoproterenol, or prostaglandin E2 either alone or in combination.
    Elliott L; Brooks W; Roszman T
    Cell Mol Neurobiol; 1992 Oct; 12(5):411-27. PubMed ID: 1334806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TNF-alpha/IFN-gamma-induced iNOS expression increased by prostaglandin E2 in rat primary astrocytes via EP2-evoked cAMP/PKA and intracellular calcium signaling.
    Hsiao HY; Mak OT; Yang CS; Liu YP; Fang KM; Tzeng SF
    Glia; 2007 Jan; 55(2):214-23. PubMed ID: 17091492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostaglandin E2 inhibits the activation of cloned T cell hybridomas.
    Makoul GT; Robinson DR; Bhalla AK; Glimcher LH
    J Immunol; 1985 Apr; 134(4):2645-50. PubMed ID: 2857750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The actions of prostaglandin E2 on potassium currents in rat tail artery vascular smooth muscle cells: regulation by protein kinase A and protein kinase C.
    Ren J; Karpinski E; Benishin CG
    J Pharmacol Exp Ther; 1996 Apr; 277(1):394-402. PubMed ID: 8613946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PGE2-induced inhibition of the PLD activation pathway stimulated by fMLP in human neutrophils is mediated by PKA at the PI3-Kgamma level.
    Burelout C; Thibault N; Harbour D; Naccache PH; Bourgoin SG
    Biochem Pharmacol; 2007 Sep; 74(5):730-41. PubMed ID: 17631865
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostaglandin E2 induces the expression of functional inhibitory CD94/NKG2A receptors in human CD8+ T lymphocytes by a cAMP-dependent protein kinase A type I pathway.
    Zeddou M; Greimers R; de Valensart N; Nayjib B; Tasken K; Boniver J; Moutschen M; Rahmouni S
    Biochem Pharmacol; 2005 Sep; 70(5):714-24. PubMed ID: 15978547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Costimulation with dexamethasone and prostaglandin E2: a novel paradigm for the induction of T-cell anergy.
    Elliott LH; Levay AK
    Cell Immunol; 1997 Sep; 180(2):124-31. PubMed ID: 9341742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adrenergic regulation of cAMP/protein kinase A pathway in corneal epithelium and endothelium.
    Grueb M; Bartz-Schmidt KU; Rohrbach JM
    Ophthalmic Res; 2008 Oct; 40(6):322-8. PubMed ID: 18688175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostaglandin E2 inhibits T cell-dependent Ig secretion by neonatal but not adult lymphocytes.
    Splawski JB; Lipsky PE
    J Immunol; 1994 Jun; 152(11):5259-67. PubMed ID: 7514634
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of type I protein kinase A during receptor-mediated human T lymphocyte activation.
    Laxminarayana D; Kammer GM
    J Immunol; 1996 Jan; 156(2):497-506. PubMed ID: 8543799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased activation of protein kinase A type I contributes to the T cell deficiency in common variable immunodeficiency.
    Aukrust P; Aandahl EM; Skålhegg BS; Nordøy I; Hansson V; Taskén K; Frøland SS; Müller F
    J Immunol; 1999 Jan; 162(2):1178-85. PubMed ID: 9916750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of a functional prostaglandin E2-protein kinase A coupling with responsiveness of metastatic Lewis lung carcinoma variants to prostaglandin E2 and to prostaglandin E2-producing nonmetastatic Lewis lung carcinoma variants.
    Young MR; Duffie GP; Lozano Y; Young ME; Wright MA
    Cancer Res; 1990 May; 50(10):2973-8. PubMed ID: 2159367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.